Tarceva Oral Tablet 100Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Tarceva: Oral tablet (100mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_8636.JPG
Tarceva 100mg Tab
Genentech Inc, a member of the Roche Group
Pill Identification: T 100 

What is this Medicine?

ERLOTINIB (er LOE ti nib) is a chemotherapy drug. It targets a specific protein within cancer cells and stops the cancer cells from growing. This medicine is used to treat cancers including non-small cell lung cancer and pancreatic cancer.

CVS Pharmacy Patient Statistics for Tarceva: Oral tablet(100mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Tarceva 100mg Tablet

NDC: 502420063
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer

Sometimes used for but not FDA approved for the following conditions:
Head And Neck Cancer

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Tarceva 100mg Tablet
Drug Image file DrugItem_8636.JPG
Genentech Inc, a member of the Roche Group
Pill Identification: T 100 
Shape: round
Color: white

Reported Side Effects for Tarceva 100mg Tablet

Bowel Obstruction Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
<4.0%*
Severity: MODERATE
Onset: DELAYED
Eye Inflammation Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Pancreas Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
Fainting Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Low Platelet Count Incidence:
0.8%*
Severity: MODERATE
Onset: DELAYED
Hemolytic Anemia Incidence:
0.8%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: DELAYED
Brain Attack Incidence:
2.3%*
Severity: SEVERE
Onset: EARLY
Heart Attack Incidence:
2.3%*
Severity: SEVERE
Onset: DELAYED
Weight Loss Incidence:
3.9%*
Severity: MILD
Onset: DELAYED
Dry Skin Incidence:
4.4-12.0%*
Severity: MILD
Onset: DELAYED
Drug-Induced Acne Incidence:
4.6%*
Severity: MILD
Onset: DELAYED
Acne Incidence:
6.2%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
7.4-13.0%*
Severity: MILD
Onset: RAPID
Tired Incidence:
9.0-52.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
9.2-52.0%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
11.0%*
Severity: MILD
Onset: EARLY
Blood Clot Incidence:
11.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Eye Incidence:
12.0%*
Severity: SEVERE
Onset: EARLY
Conjunctivitis Incidence:
12.0%*
Severity: MODERATE
Onset: DELAYED
Gas Incidence:
13.0%*
Severity: MILD
Onset: EARLY
Nerve Pain Incidence:
13.0%*
Severity: MODERATE
Onset: DELAYED
Nervousness Incidence:
13.0%*
Severity: MILD
Onset: DELAYED
Hair Loss Incidence:
14.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
15.0%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
15.0%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
15.0%*
Severity: MILD
Onset: EARLY
Mouth Sores Incidence:
17.0%*
Severity: MODERATE
Onset: DELAYED
Mouth Ulcers Incidence:
17.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
17.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
19.0%*
Severity: MODERATE
Onset: DELAYED
Loose Stools Incidence:
20.3-54.0%*
Severity: MILD
Onset: EARLY
Muscle Pain Incidence:
21.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
23.0%*
Severity: MILD
Onset: EARLY
Infection Incidence:
24.0%*
Severity: MILD
Onset: DELAYED
Bone Pain Incidence:
25.0%*
Severity: MODERATE
Onset: DELAYED
Constipation Incidence:
31.0%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
33.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
33.0%*
Severity: MILD
Onset: EARLY
Fever Incidence:
36.0%*
Severity: MILD
Onset: EARLY
Swelling Incidence:
37.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
41.0%*
Severity: MODERATE
Onset: EARLY
Skin Rash Incidence:
49.2-75.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Tarceva 100mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Tobacco and Tarceva 100mg Tablet(Erlotinib)
Tobacco and Erlotinib(Erlotinib)
Tobacco smoke contains substances that may speed the removal of Erlotinib from the body. If you start smoking, Erlotinib may become less effective. If you stop smoking, the amount of Erlotinib in the blood may increase and side effects from Erlotinib may get worse. Tell your health care professional if you smoke or if you are going to stop smoking.
Moderate Lifestyle Interaction
Grapefruit juice and Tarceva 100mg Tablet(Erlotinib)
Grapefruit juice and Erlotinib(Erlotinib)
It is recommended that you avoid or limit grapefruit-juice or grapefruit-containing foods during treatment with Erlotinib. Grapefruit products may increase the levels of Erlotinib and your risk for side effects. Notify your health care provider if you notice increased eye irritation and/or pain, shortness of breath or difficulty breathing, nausea, vomiting, mouth sores, or other unusual effects.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Tarceva

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5